SCHEMBL6566262

SCHEMBL6566262

COc1ccc(Oc2ccc(OC(CCCNCC(=O)O)c3ccccc3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 2/20 0.49
FNTA P49354 1/20 0.46
FNTB P49356 1/20 0.46
SLC6A4 P31645 6/20 0.45
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
CASR P41180 2/20 0.43
HTR1A P08908 1/20 0.43
GCGR P47871 1/20 0.42
CYP2D6 P10635 1/20 0.42
SLC6A2 P23975 1/20 0.42
NOS2 P35228 1/20 0.42
LTA4H P09960 1/20 0.42
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CTSK P43235 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6566442 0.90 FNTA (0.47) SLC6A9FNTAFNTBSLC6A4CNR1
SCHEMBL6826714 0.89 SLC6A9 (0.48) SLC6A9SLC6A4CNR1CNR2CYP2D6
SCHEMBL6566281 0.88 SLC6A4 (0.55) SLC6A9FNTAFNTBSLC6A4HTR1A
SCHEMBL6259766 0.88 SLC6A4 (0.50) SLC6A9SLC6A4CNR1HTR1ACYP2D6
SCHEMBL6566500 0.88 SLC6A9 (0.52) SLC6A9SLC6A4CNR1GCGRCYP2D6
SCHEMBL6564361 0.85 SLC6A2 (0.40) SLC6A9SLC6A4CNR1CNR2GCGR
SCHEMBL6754006 0.82 SLC6A9 (0.44) SLC6A9SLC6A4CNR1HTR1ACYP2D6
SCHEMBL6826663 0.82 MTNR1B (0.45) SLC6A9SLC6A4CNR1CASRCYP2D6
SCHEMBL6826945 0.81 HPGD (0.50) SLC6A9SLC6A4CNR2GCGRGAA
SCHEMBL7054306 0.81 KDM4E (0.44) SLC6A4GCGRCYP2D6SLC6A2NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6784299-B2 CARBOCYCLIC ETHERS SUCH AS (METHYL-(3-(4-PHENOXY-PHENOXY)-3-PHENYL-PROPYL)-AMINO)-ACETIC ACID, USED AS NEUROTRANSMITTER ANTAGONISTS, FOR PROPHYLAXIS OF PSYCHOLOGICAL DISORDERS PFIZER INC. 2004-08-31 US disclosed
EP-1406861-A1 SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT Pfizer Products Inc. (US) 2004-04-14 EP disclosed
US-20030208081-A1 Substituted aromatic ethers as inhibitors of glycine transport PFIZER INC. 2003-11-06 US disclosed
WO-2003000646-A1 SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT PFIZER PRODUCTS INC. (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030208081-A1 Substituted aromatic ethers as inhibitors of glycine transport SLC1A2, SLC1A1, SLC6A1 SLC6A9 10/4885FNTA 790/4885FNTB 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.